Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.
Recursion's share price continues to be volatile, despite its pipeline maturing and the injection of significant cash through its merger with Exscientia. While early clinical data has been ...
To get a sense of who is truly in control of Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ), it is important to understand the ownership structure of the business. With 66% stake, institutions ...
Recursion Pharmaceuticals, Inc. is a Salt Lake City based early to mid-stage biopharmaceutical concern focused on leveraging its supercomputing proficiency to develop therapies for rare diseases ...